Atencion primaria · 1992
[Vaccination against hepatitis B at the Palma-Palmilla Health Center of Málaga].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Extremera F, Hernández A, Macías B, Tarilonte M A, Badía P
Аннотация
AIM: To describe the results of a programme of anti-hepatitis B vaccination of high-risk groups.
DESIGN: Observational descriptive study, of a retrospective character. SITE. At a community level within the confines of Primary Care in the Palma-Palmilla (Málaga) Health Centre, between June 1989 and March 1990.
PATIENTS AND OTHER PARTICIPANTS: Individuals with a high risk of Hepatitis B infection, according to a modified CDC (Centre for Diseases Control) scale. The subjects were found during their attendance as patients and from among the Health Centre staff.
INTERVENTIONS: The second generation vaccine developed by genetic engineering (Engerix B) was used. It was administered by intramuscular injection in a dosage of 20 mcg to those weighing more than 25 kilos; and of 10 mcg to those weighing less than 25 kilos. The vaccination pattern was of three doses in months 0, 1 and 6, followed by a monthly sero-conversion check.
MEASUREMENTS AND MAIN FINDINGS: 169 individuals began the vaccination programme: 17.7% were health workers and 81.6% lived with carriers of the virus. 87.6% completed the vaccination programme. Sero-conversion in the individuals controlled was 95.5%. Only five patients were sero-negative after the third vaccination. Of these four cases achieved sero-conversion after a fourth or fifth dosage.
CONCLUSIONS: We found there was a high rate of sero-conversion; and also high acceptance of the programme by those living with a carrier.
DESIGN: Observational descriptive study, of a retrospective character. SITE. At a community level within the confines of Primary Care in the Palma-Palmilla (Málaga) Health Centre, between June 1989 and March 1990.
PATIENTS AND OTHER PARTICIPANTS: Individuals with a high risk of Hepatitis B infection, according to a modified CDC (Centre for Diseases Control) scale. The subjects were found during their attendance as patients and from among the Health Centre staff.
INTERVENTIONS: The second generation vaccine developed by genetic engineering (Engerix B) was used. It was administered by intramuscular injection in a dosage of 20 mcg to those weighing more than 25 kilos; and of 10 mcg to those weighing less than 25 kilos. The vaccination pattern was of three doses in months 0, 1 and 6, followed by a monthly sero-conversion check.
MEASUREMENTS AND MAIN FINDINGS: 169 individuals began the vaccination programme: 17.7% were health workers and 81.6% lived with carriers of the virus. 87.6% completed the vaccination programme. Sero-conversion in the individuals controlled was 95.5%. Only five patients were sero-negative after the third vaccination. Of these four cases achieved sero-conversion after a fourth or fifth dosage.
CONCLUSIONS: We found there was a high rate of sero-conversion; and also high acceptance of the programme by those living with a carrier.